# Bladder, Prostate and Urethra for NEET PG Surgery: Acute Retention, BPH, Prostate and Bladder Cancer, Urethral Stricture and Lower Urinary Tract Trauma

Source: https://tracknation.in/story/bladder-prostate-and-urethra-for-neet-pg-surgery-acute-retention-bph-prostate-and-bladder-cancer-urethral-stricture-and-lower-urinary-tract-trauma (TrackNation — free UPSC notes with PYQs)

> NEET PG Surgery on the ICMR 2025 acute urinary retention workflow: causes, catheterisation, suprapubic cystostomy and trial without catheter, plus BPH drugs and TURP, prostate cancer (PSA, mpMRI, Gleason, ADT), bladder cancer (TURBT, BCG, cystectomy), urethral stricture, urethral and bladder injuries, with a diagram, hooks, vignette MCQs and cards.

## Start Here

🎯 **Exam priority: High.** *Expect: ICMR acute retention steps (no tests first, 12–14 Fr catheter, SPC if it fails, alpha-blocker then
TWOC), drugs and conditions that cause retention, BPH symptoms, flow/PVR cut-offs, drugs and TURP indications/complications, prostate cancer PSA,
mpMRI, Gleason and ADT, bladder cancer risks, TURBT and BCG, stricture causes and RUG, posterior vs anterior urethral injury, blood at meatus and
bladder rupture types.*

CBME mapping: **SU29.7–29.11**. Indian anchor: ICMR STW on acute urinary retention in men (Nov 2025).

*Bladder, prostate and urethra at a glance. Drawn by TrackNation.*

## Acute Urinary Retention (ICMR)

- **Sudden, painful inability to void** with a tender, dull, palpable bladder. History: prior LUTS, fever, weight loss, leg weakness, drugs;
examine for phimosis, meatal stenosis, stone, discharge; **DRE** (size, consistency, faecal impaction) and **neuro exam** (anal tone,
perianal sensation, bulbocavernosus reflex).

- Causes that **block**: BPH, prostate cancer, stricture, urethral/vesical stone, prostatitis, faecal impaction. Causes that
**paralyse the detrusor**: cord compression, myelitis, stroke, head injury; **opioids, anticholinergics, antihistamines**.
Precipitants: anaesthesia/surgery, over-distension (long journey), cold, alcohol, diuretics.

- **No investigation before catheterising**. Gentle aseptic urethral catheterisation with a **12–14 Fr Foley**, lots of
lubricant; record the volume; keep it ≥1 day. **If it fails → suprapubic cystostomy** (if trained) or refer.

- Spontaneous AUR from BPH: **alpha-blocker for 2–4 days then trial without catheter**; failure → surgery. Watch for UTI, AKI,
**post-obstructive diuresis** with electrolyte loss, decompression haematuria, urethral injury. **Atraumatic catheterisation prevents
lifelong stricture.**

## BPH and Prostate Cancer (MSD)

- **BPH**: benign overgrowth of the **periurethral** gland → weak stream, hesitancy, frequency, **nocturia**, terminal
dribbling, overflow, retention. Score symptoms with **IPSS**; urinalysis, **PSA** (raised PSA → evaluate for cancer); flow
**<15 mL/s** = obstruction, **PVR >100 mL** = retention.

- Drugs: **alpha-blockers** (tamsulosin, alfuzosin, silodosin…), **5-alpha-reductase inhibitors** (finasteride, dutasteride),
combination; tadalafil if ED; saw palmetto no better than placebo. **Surgery** if drugs fail or complications: recurrent UTI, stones, bladder
dysfunction, upper-tract dilatation (and refractory retention). **TURP** is the standard; commonest after-effect **retrograde
ejaculation**.

- **Prostate cancer**: adenocarcinoma; commonest non-skin cancer in men >50 (US); slow, usually silent until late (haematuria, outflow
symptoms, **osteoblastic bone metastases** to pelvis, ribs, spine). PSA >10 → 67% PPV. **mpMRI then biopsy**; **Gleason**
≤6 well, 7 moderate, 8–10 poor. Screening needs shared decisions.

- Localised: active surveillance, radical prostatectomy (incontinence, stricture, ED) or radiotherapy. Metastatic: **androgen deprivation**
(LHRH agonists/antagonists ≈ orchiectomy) ± abiraterone/enzalutamide or docetaxel. More men die with it than of it.

## Bladder Cancer, Stricture and Trauma (MSD)

- **Bladder cancer**: **urothelial >90%**; **haematuria** commonest, also irritative symptoms. Risks:
**smoking (≥50%)**, cyclophosphamide, **aniline dyes**/aromatic amines, chronic irritation (catheters, stones,
**schistosomiasis → squamous cell**). **Cystoscopy and biopsy**. Non-muscle-invasive: **TURBT** + intravesical chemo;
high grade → **intravesical BCG**. Muscle-invasive: **radical cystectomy** or chemoradiation. Recurs in >40%.

- **Urethral stricture**: scarring of the anterior urethra; **trauma (straddle, catheter/endoscope) commonest**, gonorrhoea,
lichen sclerosus. Slow stream, recurrent UTI, **difficult catheterisation**. **Retrograde urethrogram** or cystoscopy. Dilation or
**internal urethrotomy**; self-catheterisation; **urethroplasty** for recurrent localised strictures.

- **Urethral injury**: **posterior with pelvic fracture**; **anterior with straddle** or perineal blow.
**Blood at the meatus** is the key sign; high-riding prostate is unreliable. **Retrograde urethrogram before any catheter.** Contusion →
catheter 5–7 days; partial disruption → **suprapubic cystostomy**; delayed repair.

- **Bladder injury**: with pelvic fracture and gross haematuria; **retrograde (CT) cystography with ≥300 mL**. Most are
**extraperitoneal → catheter drainage**; **intraperitoneal (urinary ascites) and penetrating → surgery**, as is bladder-neck injury.

## Traps the Examiner Sets

- Blood at the meatus: urethrogram first, never a blind catheter.

- Retention: catheterise first, investigate later.

- Prostate metastases are osteoblastic.

- Intraperitoneal bladder rupture needs surgery; extraperitoneal usually doesn't.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **Retention causes: 'Block or Paralyse' — prostate/stricture/stone vs cord/drugs** — retention

- 🧠 **'Tube first, tests later' in acute retention** — management

- 🧠 **'Blood at the tip? Picture before the pipe' (urethrogram before catheter)** — urethral injury

- 🧠 **Bladder rupture: 'Intra goes to theatre, Extra gets a catheter'** — bladder injury

- 🧠 **'Prostate builds bone' — osteoblastic metastases** — prostate cancer

## Rapid-Revision Cards

- Catheter; no tests.

- 12–14 Fr Foley.

- Suprapubic cystostomy.

- Opioids, anticholinergics.

- Alpha-blocker 2–4 d → TWOC.

- Diuresis; electrolytes.

- Periurethral overgrowth.

- <15 mL/s; >100 mL.

- Alpha-blocker; finasteride.

- Recurrent UTI, stones, hydronephrosis.

- Retrograde ejaculation.

- Osteoblastic.

- PPV 67%.

- mpMRI.

- Poorly differentiated.

- Smoking ≥50%.

- Squamous bladder cancer.

- TURBT; BCG.

- Trauma; RUG.

- RUG before catheter.

- Extra: catheter; intra: surgery.

## Sources

*Facts in this article were checked against these documents.*

- Standard Treatment Workflow: Acute Urinary Retention in Men — ICMR / Department of Health Research, Nov 2025

- MSD Manual Professional: Benign Prostatic Hyperplasia; Prostate Cancer; Bladder Cancer; Urethral Stricture; Urethral Trauma; Bladder Trauma — Merck & Co. (MSD Manuals), 2025–26 (link)

- Competency Based Undergraduate Curriculum, Vol III: General Surgery (SU29) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** A 70-year-old man has a sudden painful inability to pass urine and a tender, dull suprapubic swelling. Per ICMR, the first step is

- (a) cystoscopy

- (b) IV furosemide

- (c) ultrasound KUB first

- (d) gentle urethral catheterisation without waiting for tests

**Answer: (d)** — Tests can wait.

**Q2.** The catheter size ICMR recommends for acute retention is

- (a) 22–24 Fr three-way

- (b) 12–14 Fr Foley

- (c) 8 Fr feeding tube

- (d) 30 Fr

**Answer: (b)** — Adequate lubrication.

**Q3.** Urethral catheterisation fails in acute retention. The next step (if trained) is

- (a) suprapubic cystostomy

- (b) forceful repeated catheter attempts

- (c) diuretics

- (d) observe till morning

**Answer: (a)** — Else refer.

**Q4.** A drug class that can cause acute retention by paralysing the detrusor is

- (a) alpha-blockers

- (b) anticholinergics

- (c) 5-alpha-reductase inhibitors

- (d) PPIs

**Answer: (b)** — Also opioids, antihistamines.

**Q5.** After catheterisation for spontaneous retention due to BPH, ICMR advises

- (a) antibiotics only

- (b) an alpha-blocker for 2–4 days then trial without catheter

- (c) immediate TURP

- (d) lifelong catheter

**Answer: (b)** — Surgery if TWOC fails.

**Q6.** After relief of chronic retention, a patient passes large volumes of urine with falling sodium and potassium. This is

- (a) acute tubular necrosis only

- (b) post-obstructive diuresis

- (c) SIADH

- (d) diabetes insipidus always

**Answer: (b)** — Watch electrolytes.

**Q7.** In a man with acute retention, the neurological examination should include

- (a) fundoscopy only

- (b) gag reflex

- (c) anal tone, perianal sensation and bulbocavernosus reflex

- (d) plantar only

**Answer: (c)** — Cord compression.

**Q8.** BPH arises from overgrowth of the

- (a) periurethral prostate gland

- (b) seminal vesicles

- (c) bladder neck muscle

- (d) peripheral zone only

**Answer: (a)** — Outflow obstruction.

**Q9.** On uroflowmetry, obstruction is suggested by a maximum flow below

- (a) 15 mL/s

- (b) 5 L/min

- (c) 100 mL/s

- (d) 40 mL/s

**Answer: (a)** — PVR >100 mL = retention.

**Q10.** A 5-alpha-reductase inhibitor used in BPH is

- (a) finasteride

- (b) tamsulosin

- (c) oxybutynin

- (d) sildenafil

**Answer: (a)** — Also dutasteride.

**Q11.** An indication for surgery in BPH is

- (a) nocturia once

- (b) recurrent UTI, bladder stones or upper-tract dilatation

- (c) mild symptoms responding to drugs

- (d) PSA of 2

**Answer: (b)** — Or drug failure.

**Q12.** The commonest sequel of TURP is

- (a) retrograde ejaculation

- (b) urethral cancer

- (c) impotence in all

- (d) permanent incontinence

**Answer: (a)** — Continence usually kept.

**Q13.** Herbal saw palmetto for BPH

- (a) is first-line

- (b) replaces TURP

- (c) cures BPH

- (d) is no better than placebo

**Answer: (d)** — MSD.

**Q14.** Bone metastases from prostate cancer are typically

- (a) absent

- (b) purely soft tissue

- (c) osteoblastic

- (d) osteolytic

**Answer: (c)** — Pelvis, ribs, spine.

**Q15.** An asymptomatic man has PSA 12 ng/mL. The positive predictive value for cancer is about

- (a) 5%

- (b) 67%

- (c) 25%

- (d) 100%

**Answer: (b)** — 25% for PSA 4–10.

**Q16.** The current first imaging before prostate biopsy is

- (a) multiparametric MRI

- (b) CT KUB

- (c) IVP

- (d) bone scan

**Answer: (a)** — Then needle biopsy.

**Q17.** A Gleason score of 8–10 indicates

- (a) inflammation

- (b) poorly differentiated tumour

- (c) well differentiated

- (d) benign hyperplasia

**Answer: (b)** — ≤6 well, 7 moderate.

**Q18.** For metastatic prostate cancer, the backbone of treatment is

- (a) TURP

- (b) androgen deprivation therapy

- (c) radical prostatectomy

- (d) BCG

**Answer: (b)** — LHRH agonists ≈ orchiectomy.

**Q19.** The most common risk factor for bladder cancer is

- (a) bladder stones

- (b) smoking

- (c) schistosomiasis

- (d) cyclophosphamide

**Answer: (b)** — ≥50% of cases.

**Q20.** Bladder cancer in a patient with chronic schistosomiasis is most likely

- (a) sarcoma

- (b) urothelial carcinoma

- (c) adenocarcinoma

- (d) squamous cell carcinoma

**Answer: (d)** — Chronic irritation.

**Q21.** A dye-industry worker who smokes has haematuria. The definitive test is

- (a) plain X-ray

- (b) PSA

- (c) urine culture

- (d) cystoscopy and biopsy

**Answer: (d)** — Aniline dyes.

**Q22.** High-grade non-muscle-invasive bladder cancer after complete TURBT is treated with

- (a) observation only

- (b) radical prostatectomy

- (c) intravesical BCG

- (d) oral tamoxifen

**Answer: (c)** — Or cystectomy.

**Q23.** Muscle-invasive bladder cancer is treated by

- (a) TURBT alone

- (b) BCG alone

- (c) radical cystectomy or chemoradiation

- (d) observation

**Answer: (c)** — MSD.

**Q24.** The most common cause of urethral stricture is

- (a) cancer

- (b) trauma (straddle injury or instrumentation)

- (c) lichen sclerosus

- (d) gonorrhoea

**Answer: (b)** — Anterior urethra.

**Q25.** A man with a slow stream cannot be catheterised. Stricture is confirmed by

- (a) PSA

- (b) retrograde urethrogram or cystoscopy

- (c) IVP

- (d) renal scan

**Answer: (b)** — Then urethrotomy or urethroplasty.

**Q26.** A recurrent, localised urethral stricture that keeps failing dilation is best treated by

- (a) TURP

- (b) open urethroplasty

- (c) cystectomy

- (d) repeated dilation forever

**Answer: (b)** — MSD.

**Q27.** After a pelvic fracture, a man has blood at the urethral meatus and cannot void. Next step:

- (a) retrograde urethrogram before any catheter

- (b) IVP

- (c) cystoscopy

- (d) urethral catheter at once

**Answer: (a)** — Posterior urethral injury.

**Q28.** A man falls astride a beam and has perineal bruising and blood at the meatus. The injured segment is most likely the

- (a) anterior (bulbar) urethra

- (b) bladder neck

- (c) posterior (membranous) urethra

- (d) ureter

**Answer: (a)** — Straddle injury.

**Q29.** A partial urethral disruption is best managed initially by

- (a) immediate urethroplasty in all

- (b) urethral catheter by force

- (c) observation

- (d) suprapubic cystostomy

**Answer: (d)** — Delayed repair.

**Q30.** CT cystography after blunt trauma shows an intraperitoneal bladder rupture. Management:

- (a) catheter drainage alone

- (b) suprapubic aspiration

- (c) surgical exploration and repair

- (d) observation

**Answer: (c)** — Extraperitoneal: catheter.

### Active Recall

From memory: outline the ICMR approach to acute urinary retention and its causes, describe BPH evaluation and treatment, summarise prostate and bladder cancer, and describe urethral stricture, urethral injuries and bladder rupture management.
